NASDAQ:GOSS

Gossamer Bio - GOSS Stock Forecast, Price & News

$8.56

0.00 (0.00%)

(As of 11/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $8.15
▼
$8.81
50-Day Range: $8.56
▼
$12.87
52-Week Range: $5.64
▼
$15.19

Volume: 3.25 million shs
Average Volume: 1.11 million shs
Market Capitalization: $808.72 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $20.30

Gossamer Bio MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.90 Rating Score
Upside/Downside: 137.1% Upside
$20.30 Price Target
Short Interest: Bearish
27.05% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.67
Upright™ Environmental Score
News Sentiment: 0.64
Based on 3 Articles This Week
Insider Trading: Selling Shares
$116,270 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.75) to ($2.51) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

552nd out of 1,043 stocks

Pharmaceutical Preparations Industry

260th out of 510 stocks

3.5

Analyst's Opinion

Consensus Rating
Gossamer Bio has received a consensus rating of Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $20.30, Gossamer Bio has a forecasted upside of 137.1% from its current price of $8.56.
Amount of Analyst Coverage
Gossamer Bio has only been the subject of 4 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
27.05% of the float of Gossamer Bio has been sold short.
Short Interest Ratio / Days to Cover
Gossamer Bio has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.
Change versus previous month
Short interest in Gossamer Bio has recently increased by 0.79%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Gossamer Bio does not currently pay a dividend.
Dividend Growth
Gossamer Bio does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Gossamer Bio has received a 76.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Gossamer Bio is -0.67.

2.6

News and Social Media Coverage

News Sentiment
Gossamer Bio has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Gossamer Bio this week, compared to 1 article on an average week.
Search Interest
6 people have searched for GOSS on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Gossamer Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $116,270.00 in company stock.
Percentage Held by Insiders
Only 8.30% of the stock of Gossamer Bio is held by insiders.
Percentage Held by Institutions
67.57% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Gossamer Bio are expected to grow in the coming year, from ($2.75) to ($2.51) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Gossamer Bio is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Gossamer Bio is -2.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Gossamer Bio has a P/B Ratio of 14.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Gossamer Bio (NASDAQ:GOSS) Stock

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Receive GOSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

GOSS Stock News Headlines

November 25, 2022 | finance.yahoo.com

Analyst Expects 'Somewhat Smaller Effect Size' From Gossamer Bio's Upcoming PAH Trial

November 23, 2022 | americanbankingnews.com

Stock Traders Buy Large Volume of Gossamer Bio Call Options (NASDAQ:GOSS)

November 30, 2022 | Tradewins (Ad)

The Safest Option in Trades!

If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult. And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

November 21, 2022 | americanbankingnews.com

Gossamer Bio (NASDAQ:GOSS) Given New $15.00 Price Target at Raymond James

November 17, 2022 | markets.businessinsider.com

4 Analysts Have This to Say About Gossamer Bio

November 8, 2022 | msn.com

What Makes Gossamer Bio (GOSS) a New Buy Stock

November 3, 2022 | finance.yahoo.com

Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update

October 24, 2022 | finance.yahoo.com

Goldman Sachs Says These 2 Buy-Rated Stocks Have at Least 60% Upside Potential

November 30, 2022 | Tradewins (Ad)

The Safest Option in Trades!

October 20, 2022 | forbes.com

Gossamer Bio

October 20, 2022 | cnbc.com

Goldman says buy this under-the-radar biopharma stock expected to rally nearly 80%

October 20, 2022 | markets.businessinsider.com

What 5 Analyst Ratings Have To Say About Gossamer Bio

October 18, 2022 | finance.yahoo.com

Gossamer Bio, Inc. (GOSS)

October 17, 2022 | nasdaq.com

Gossamer Bio, Inc. (NASDAQ:GOSS) is favoured by institutional owners who hold 62% of the company

October 7, 2022 | nasdaq.com

January 2023 Options Now Available For Gossamer Bio

September 27, 2022 | seekingalpha.com

Peaking Back In On Gossamer Bio

September 20, 2022 | benzinga.com

1GOSS : Where Gossamer Bio Stands With Analysts

September 20, 2022 | benzinga.com

7GOSS : What 4 Analyst Ratings Have To Say About Gossamer Bio

September 19, 2022 | seekingalpha.com

Wedbush expects positive phase 2 data readout from Gossamer Bio, starts with outperform

September 19, 2022 | markets.businessinsider.com

What 4 Analyst Ratings Have To Say About Gossamer Bio

September 14, 2022 | americanbankingnews.com

Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Average Recommendation of "Buy" from Analysts

August 29, 2022 | finance.yahoo.com

With 62% ownership of the shares, Gossamer Bio, Inc. (NASDAQ:GOSS) is heavily dominated by institutional owners

August 16, 2022 | seekingalpha.com

Gossamer Bio (GOSS) Investor Presentation - Slideshow

August 9, 2022 | finance.yahoo.com

Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update

July 22, 2022 | finance.yahoo.com

2 ‘Strong Buy’ Stocks That ‘In-The-Know’ Bigwigs Are Pouring Money Into

July 20, 2022 | finance.yahoo.com

‘Squeezable’ AMC, GameStop stocks break out to multi-month highs

July 19, 2022 | seekingalpha.com

Daily Biotech/Pharma Pulse: July 18, Featuring Gossamer Bio (GOSS)

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive GOSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

GOSS Company Calendar

Last Earnings: 11/03/2022
Today: 11/30/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/02/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GOSS
CUSIP: N/A
CIK: 1728117
Web: www.gossamerbio.com
Phone: (858) 684-1300
Fax: N/A
Employees: 185
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $20.30
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $15.00
Forecasted Upside/Downside: +137.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.90
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-234,000,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -480.17%
Return on Assets: -76.14%

Debt

Debt-to-Equity Ratio: 3.73
Current Ratio: 5.93
Quick Ratio: 5.93

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.60 per share
Price / Book: 14.27

Miscellaneous

Outstanding Shares: 94,477,000
Free Float: 86,635,000
Market Cap: $808.72 million
Optionable: Not Optionable
Beta: 0.88

Key Executives

Mr. Faheem Hasnain (Age 64)
Co-Founder, CEO, Pres & Chairman
Comp: $895.56k

Mr. Bryan Giraudo (Age 47)
COO & CFO
Comp: $651.8k

Mr. Christian Waage (Age 55)
Exec. VP of Technical Operations & Admin.
Comp: $583.16k

Dr. Laura L. Carter Ph.D. (Age 55)
Chief Scientific Officer

Mr. Jeff Boerneke
Gen. Counsel & Sec.

Ms. Deanna Weber
Sr. VP of HR

Dr. Richard Aranda M.D. (Age 62)
Chief Medical Officer

Mr. Mario Orlando
Sr. VP of Commercial New Product Planning

Ms. Caryn L. Peterson (Age 63)
Exec. VP of Regulatory Affairs

Mr. Matt Cravets
Sr. VP of Biometrics

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GOSS Stock - Frequently Asked Questions

Should I buy or sell Gossamer Bio stock right now?: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GOSS shares.
View GOSS analyst ratings or view top-rated stocks.
What is Gossamer Bio's stock price forecast for 2023?: 10 Wall Street analysts have issued twelve-month target prices for Gossamer Bio's stock. Their GOSS share price forecasts range from $15.00 to $25.00. On average, they predict the company's stock price to reach $20.30 in the next year. This suggests a possible upside of 137.1% from the stock's current price.
View analysts price targets for GOSS or view top-rated stocks among Wall Street analysts.
How have GOSS shares performed in 2022?: Gossamer Bio's stock was trading at $11.31 at the beginning of 2022. Since then, GOSS stock has decreased by 24.3% and is now trading at $8.56.
View the best growth stocks for 2022 here.
When is Gossamer Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our GOSS earnings forecast.
How were Gossamer Bio's earnings last quarter?: Gossamer Bio, Inc. (NASDAQ:GOSS) issued its quarterly earnings results on Thursday, November, 3rd. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.66) by $0.01.
What other stocks do shareholders of Gossamer Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Gossamer Bio investors own include Editas Medicine (EDIT), Alector (ALEC), Sorrento Therapeutics (SRNE), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Stoke Therapeutics (STOK), Precision BioSciences (DTIL) and Invitae (NVTA).

When did Gossamer Bio IPO?: (GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.
What is Gossamer Bio's stock symbol?: Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS."
Who are Gossamer Bio's major shareholders?: Gossamer Bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.78%), BlackRock Inc. (5.83%), EcoR1 Capital LLC (4.40%), State Street Corp (4.00%), Boxer Capital LLC (3.78%) and NEA Management Company LLC (3.67%). Insiders that own company stock include Bryan Giraudo, Caryn Peterson, Faheem Hasnain, Jakob Dupont, Laura Carter, Luisa Salter-Cid, Richard Aranda and Waage Christian.
View institutional ownership trends.
How do I buy shares of Gossamer Bio?: Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Gossamer Bio's stock price today?: One share of GOSS stock can currently be purchased for approximately $8.56.
How much money does Gossamer Bio make?: Gossamer Bio (NASDAQ:GOSS) has a market capitalization of $808.72 million. The company earns $-234,000,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis.
How many employees does Gossamer Bio have?: The company employs 185 workers across the globe.
How can I contact Gossamer Bio?: Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The official website for the company is www.gossamerbio.com. The company can be reached via phone at (858) 684-1300 or via email at ir@gossamerbio.com.

This page (NASDAQ:GOSS) was last updated on 11/30/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Gossamer Bio - GOSS Stock Forecast, Price & News

Gossamer Bio MarketRank™ Forecast

Overall MarketRank™